enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year is $33.67.

ENGN has been the subject of several research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th.

enGene Trading Down 6.0 %

enGene stock opened at $7.90 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52. enGene has a one year low of $4.42 and a one year high of $18.40. The business has a fifty day moving average of $7.52 and a two-hundred day moving average of $9.01.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. Research analysts forecast that enGene will post -1.54 EPS for the current fiscal year.

Insider Transactions at enGene

In other news, major shareholder Growth Opportunities F. Forbion bought 11,844 shares of enGene stock in a transaction on Monday, October 7th. The shares were bought at an average cost of $6.55 per share, for a total transaction of $77,578.20. Following the acquisition, the insider now owns 2,469,833 shares in the company, valued at approximately $16,177,406.15. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other enGene news, major shareholder Growth Opportunities F. Forbion acquired 341,332 shares of the stock in a transaction dated Monday, September 30th. The stock was acquired at an average price of $6.34 per share, with a total value of $2,164,044.88. Following the completion of the transaction, the insider now directly owns 2,400,791 shares in the company, valued at approximately $15,221,014.94. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Growth Opportunities F. Forbion bought 11,844 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was acquired at an average price of $6.55 per share, with a total value of $77,578.20. Following the completion of the purchase, the insider now directly owns 2,469,833 shares of the company’s stock, valued at approximately $16,177,406.15. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 420,965 shares of company stock valued at $2,651,103 over the last three months. 13.70% of the stock is currently owned by insiders.

Institutional Trading of enGene

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the first quarter worth approximately $2,039,000. Janus Henderson Group PLC acquired a new stake in shares of enGene during the 1st quarter worth $17,095,000. SR One Capital Management LP purchased a new position in shares of enGene in the 2nd quarter worth $4,715,000. Logos Global Management LP grew its position in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. Finally, Wolverine Asset Management LLC acquired a new stake in enGene during the third quarter worth about $37,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.